GovBidAlerts
← All opportunities

FDA-RFQ- BioProfile FLEX2 Parts and Components-Brand Name or Equal

Key dates

Posted
Jun 16, 2026
Response deadline
Jun 26, 2026, 4:00 PM UTC
Archive date
Archive type
auto15

Classification

Notice type
Combined Synopsis/Solicitation
Base type
Combined Synopsis/Solicitation
Set-aside
No Set aside used
Set-aside code
NONE
PSC
6640

NAICS

Issuing office

Department
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
FOOD AND DRUG ADMINISTRATION
Office
FDA OFFICE OF ACQ GRANT SVCS
Office code
075.7524.75F401
Organization type
OFFICE
Office address
Rockville, MD, 20852, USA

Place of performance

Street
Street 2
City
Silver Spring
State
Maryland
Zip
Country
UNITED STATES

Contacts

Description

Request for Quotation: FDA-RFQ-CDER-2026-133117 BioProfile FLEX2 Parts and Components-Brand Name or Equal Notice of Combined Synopsis/Solicitation – This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with part 12. This announcement constitutes the only solicitation; quotes are being requested, and a separate written solicitation will not be issued. Background – The Center for Drug Evaluation and Research (CDER) requires operational parts and consumables for three (3) currently owned Nova BioProfile Flex 2 instruments. To meet the purpose and objective of this requirement, a single Contractor shall provide the parts and components listed in the Statement of Work (SOW) that must be compatible with the corresponding three (3) NOVA BioProfile Flex 2 instruments: Main FLEX2 instrument 1: Serial Number- T262230070C Main FLEX2 instrument 2: Serial Number- T26817050C External sampling module for instrument 2: T2761720PC Main FLEX2 instrument 3: Serial Number- T26A200050C Please note Main FLEX2 instrument 2 has two serial numbers because it has an additional module added which has its own Serial Number. The offeror is also expected to adhere to the: the established delivery times as expressed in Section 5.1 of the attached combined solicitation/synopsis the fullest extent practicable. Minimum Salient Characteristic Requirements: 1. Compatibility is needed for three currently owned Nova BioProfile Flex 2 instruments as described in this Section (Section 5). The Contractor shall identify the following salient characteristics for BioProfile Flex-2 commercial parts and consumables or equal 2. Instrument identity: Manufacturer (Nova Biomedical), instrument name and model (BioProfile FLEX 2), and all three serial numbers of the government-owned instruments 3. Instrument function: Automated bioanalysis system for cell culture monitoring, measuring parameters such as pH, dissolved gases, metabolites, osmolality, and cell density 4. Compatibility requirement: All parts and consumables supplied must be fully compatible with and functional in the Nova BioProfile FLEX 2 as configured at the FDA facility, without modification to the instrument 5. Quality standard: All items must be new, unused, and free from defects; grey market and refurbished products are unacceptable 6. Shelf life: All items must arrive with at least 75% to 80% of their total shelf life remaining upon delivery 7. Cold chain: Items requiring refrigeration or classified as flammable must be shipped and delivered in accordance with manufacturer specifications and applicable DOT/IATA regulations 8. Authorization: Offeror must be the manufacturer or an authorized reseller of the items quoted Place of Performance: Food and Drug Administration Attn: Erica Berilla 10903 New Hampshire Ave Bldg. 52/72 RM 2232 Silver Spring, MD 20903 Period of Performance: 12 consecutive months commencing upon date of Award. Please see the attached Statement of Work and Corresponding Justification for reference/utilization. Quotes are due by email on or before June 26, 2025, by 12:00 P.M. (Eastern Daylight Time) and should be sent to brandon.rafus@fda.hhs.gov.

Attachments (2)

Similar open contracts

Metadata

Notice ID
f8159aeb3a864bfb85526f7d66b8c965
Full path
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.FOOD AND DRUG ADMINISTRATION.FDA OFFICE OF ACQ GRANT SVCS
Office code
075.7524.75F401
Ingested
Jun 17, 2026
Updated
Jul 11, 2026